Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
Most patients (83%) responded to the treatment, with 63% having a complete response.
The study evaluated an NGS assay and its correlation with RT-PCR assay results for BCR::ABL in patients with Ph+ ALL.
The two-year PFS rate was 58.2%, while the five-year PFS rate was 44% at a median follow-up of 92.8 months.
Anastasia Tikhonova, PhD, was named a 2023 NextGen Star by the AACR.
The 18-month overall survival rate was 75%, while the event-free survival rate was 53.1%.
Advertisement
Anastasia Tikhonova, PhD, talks about her research on the immune microenvironment in T-cell ALL.
AUTO1 is a “fast off-rate CD19 binding domain CAR designed to reduce immune toxicity and improve engraftment."
The study’s authors did not report any new or unexpected long-term adverse events.
The researchers studied real-world outcomes of pediatric patients with B-cell ALL who recieved tisagenlecleucel.
No relapses occurred in patients who achieved early MRD negativity per the next-generation sequencing MRD assay.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
The efficacy of CNS prophylaxis with intrathecal chemotherapy in Ph+ ALL depends upon how many times it is given.
Ponatinib plus hyper-CVAD led to "excellent" outcomes in patients with newly diagnosed Ph+ ALL.
A chemotherapy-free regimen with ponatinib and blinatumomab led to high complete molecular response rates in Ph+ ALL.
A chemotherapy-free regimen led to high rates of complete remission and MRD negativity in patients with Ph+ ALL.
Inotuzumab ozogamicin plus hyper-CVAD with sequential blinatumomab is safe and effective for Ph-negative B-cell ALL.
Adding blinatumomab to consolidation chemotherapy led to improved survival in MRD-negative patients with B-lineage ALL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726